Schrödinger (SDGR) Competitors

Blueprint Medicines (NASDAQ:BPMC) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Do institutionals and insiders believe in BPMC or SDGR?

79.1% of Schrödinger shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by company insiders. Comparatively, 8.6% of Schrödinger shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is BPMC or SDGR more profitable?

Blueprint Medicines has a net margin of -13.19% compared to Schrödinger's net margin of -91.84%. Schrödinger's return on equity of -35.77% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-13.19%	-77.49%	-20.84%
Schrödinger	-91.84%	-35.77%	-24.51%

Which has higher earnings & valuation, BPMC or SDGR?

Schrödinger has lower revenue, but higher earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Schrödinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$508.82M	11.27	-$67.09M	-$1.08	-83.10
Schrödinger	$207.54M	7.46	$40.72M	-$2.57	-8.26

Which has more volatility & risk, BPMC or SDGR?

Blueprint Medicines has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Do analysts rate BPMC or SDGR?

Blueprint Medicines presently has a consensus price target of $123.83, suggesting a potential upside of 37.98%. Schrödinger has a consensus price target of $32.29, suggesting a potential upside of 52.00%. Given Schrödinger's stronger consensus rating and higher possible upside, analysts clearly believe Schrödinger is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65
Schrödinger	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the media refer more to BPMC or SDGR?

In the previous week, Schrödinger had 12 more articles in the media than Blueprint Medicines. MarketBeat recorded 21 mentions for Schrödinger and 9 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.88 beat Schrödinger's score of 0.00 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Blueprint Medicines	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrödinger	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor BPMC or SDGR?

Blueprint Medicines received 491 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 68.08% of users gave Blueprint Medicines an outperform vote while only 57.89% of users gave Schrödinger an outperform vote.

Company	Underperform	Outperform
Blueprint Medicines	Outperform Votes 546 68.08%	Underperform Votes 256 31.92%
Schrödinger	Outperform Votes 55 57.89%	Underperform Votes 40 42.11%

Summary

Blueprint Medicines and Schrödinger tied by winning 9 of the 18 factors compared between the two stocks.